Tissuemed
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
 | |
| Company type | Private |
|---|---|
| Industry | Medical Devices |
| Headquarters | Leeds, West Yorkshire, U.K. |
| Products | TissuePatch product family of surgical sealant films |
| Website | www.tissuemed.com |
Tissuemed is a medical device developer and manufacturer based in Leeds, UK.
The company was founded in 1985 and developed the first tissue heart valve (derived from pigs) to receive regulatory approval (CE mark) in Europe. This business was divested in 1999,[1] and the heart values are currently sold by Vascutek, a Terumo company, under the Aspire brand.[2][3] Thereafter, Tissuemed focused on the development of innovative tissue adhesives for internal surgical use, including a light activated tissue sealant to prevent blood loss during vascular anastomosis, the TissueBond system.[4][5]
More recently in 2007, Tissuemed launched TissuePatch, a range of surgical sealant films for the prevention of leaks during surgery, including thoracic, general and neurosurgery.[6][7]
These products incorporate a unique synthetic bioadhesive that forms a covalent bond with tissue proteins, enabling adhesion to internal organs and achieving a sealing effect. In June 2016, Tissuemed won approval from China's FDA for its TissuePatch surgical sealant.[8]
The company was acquired by Becton Dickinson in 2021.[9]
References[edit]
- ^ AorTech buys TissueMed's heart valve division. Elservier Business Intelligence, 1999. http://www.elsevierbi.com/deals/199910268
- ^ Kumar, P; Athanasiou T; Mussa S; Wood AJ. (2003). "Ten year experience with Aspire (Tissuemed) porcine bioprosthesis: single centre experience". Cardiovascular Surgery. 11 (2): 131–7. doi:10.1016/s0967-2109(03)00011-5. PMID 12664048.
- ^ Goldsmith, IR; Spyt TJ; Boehm M; Kendall S; Rosin MD. (2001). "Midterm evaluation of the Tissuemed (Aspire) porcine bioprosthesis: 493 patients, 506 bioprostheses". The Annals of Thoracic Surgery. 71 (5): 1471–6. doi:10.1016/s0003-4975(01)02397-9. PMID 11383785.
- ^ Birch, JF; Mandley DJ; Williams SL; Worrall DR; Trotter PJ; Wilkinson F; Bell PR. (2000). "Methylene blue based protein solder for vascular anastomoses: an in vitro burst pressure study". Lasers in Surgery and Medicine. 26 (3): 323–9. doi:10.1002/(sici)1096-9101(2000)26:3<323::aid-lsm11>3.0.co;2-r. PMID 10738296. S2CID 35428707.
- ^ US patent 6,239,190, "Enhancement of activation for biological tissue adhesives, bonding agents and sealants using "color change" chromophores", published 2001, assigned to Tissuemed Ltd
- ^ Ferroli, P; Acerbi, F; Broggi, M; Schiariti, M; Albanese, E; Tringali, G; Franzini, A; Broggi, G (March–April 2013). "A novel impermeable adhesive membrane to reinforce dural closure: a preliminary retrospective study on 119 consecutive high-risk patients". World Neurosurgery. 79 (3–4): 551–7. doi:10.1016/j.wneu.2011.09.022. PMID 22120260.
- ^ Schiariti M, Acerbi F, Broggi M, Tringali G, Raggi A, Broggi G, Ferroli P. Two alternative dural sealing techniques in posterior fossa surgery: (Polylactide-co-glycolide) self-adhesive resorbable membrane versus polyethylene glycol hydrogel. Surg Neurol Int. 2014 Dec 3;5:171. doi: 10.4103/2152-7806.146154.
- ^ "Tissuemed wins China's OK for TissuePatch surgical sealant – MassDevice". www.massdevice.com. June 2016. Retrieved October 16, 2017.
- ^ Wright, Greg (December 14, 2021). "Leeds based medical device manufacturer Tissuemed is acquired by US-based Becton Dickinson". Yorkshire Post. Retrieved August 25, 2022.